Tender Offer Rocks Applied Therapeutics as Shares Plunge 35%

Introduction

Applied Therapeutics Inc. (ticker: APLT) is a clinical-stage biopharmaceutical company based in New York and listed on the NASDAQ. Established in 2016, the company focuses on developing treatments for rare diseases with high unmet medical needs through molecular-targeted science and biomarker guidance.

Corporate Structure

Applied Therapeutics employs a workforce of 11 to 50 individuals. Its leadership team possesses a combination of drug development experience alongside expertise in translational biology, crystallography, and regulatory strategy. The company holds global rights to its lead candidates and has an exclusive license and supply agreement with Mercury Pharma Group Limited for its therapy targeting galactosemia.

Biopharmaceuticals by little plant

Recent Developments and News

On December 11, 2025, Cycle Group Holdings Limited submitted a tender offer to acquire all outstanding shares of Applied Therapeutics at $0.088 per share, accompanied by a non-tradable contingent value right (CVR) that may yield up to $0.40 per CVR upon achievement of specific milestones in the company's pipeline. Applied Therapeutics filed a Form SC 14D9C on December 12, 2025, which contains details regarding transaction terms, closing conditions, and potential risks associated with the offer, including shareholder participation levels and legal proceedings.

In regulatory filings dated November 20, 2025 (Form 8-K), the company reported developments under Items 8.01 and 9.01; however, specific details were not disclosed in public summaries.

Throughout 2025, Applied Therapeutics engaged with patient and research communities at the following events:

• The ASHG Annual Meeting (November 2025, Boston) focusing on PMM2-CDG research
• The Neuromuscular Study Group Annual Meeting (#NMSG2025)
• Events for CMT Awareness Month in September 2025 in Denver and Boston
• The CMTA Patient & Research Summit (September 5–7, 2025, Indianapolis)

These activities demonstrate the company’s involvement with genetic disorders, including congenital disorders of glycosylation and Charcot-Marie-Tooth disease.

Financial and Strategic Analysis

As of December 12, 2025, APLT shares closed at $0.1400, representing a decrease of 35.45% for that trading session, with a volume of 856,459 shares. According to Yahoo Finance data, as of the most recent reporting period, the company’s market capitalization is approximately $31.3 million, with trailing twelve-month revenue of $1 million, a net loss of $18.14 million, and total cash of $11.95 million.

The pipeline of Applied Therapeutics includes:

• AT-007 (govorestat): completed Phase 3 12-month interim data for SORD deficiency; Phase 2 ready for PMM2-CDG with expanded access; pediatric and adult studies for galactosemia
• AT-001: in Phase 3 trials for diabetic cardiomyopathy and diabetic peripheral neuropathy
• AT-003: preclinical candidate for diabetic retinopathy

The company’s aldose reductase inhibitors utilize advanced crystallography to enhance binding specificity and reduce off-target effects, aiming to streamline the transition from clinical trials to regulatory approval.

A Zacks Rank upgrade to #2 (Buy) is associated with upward revisions in earnings estimates, indicating potentially improved expectations for future profitability. The tender offer offers immediate liquidity for shareholders.

Market Position and Industry Context

Applied Therapeutics operates within the rare-disease sector of biotechnology research, where high development costs and regulatory challenges are balanced by potential orphan-drug incentives. The company's small market capitalization and negative free cash flow (–$128.16 million trailing twelve months) make its valuation sensitive to clinical readouts and the achievement of pipeline milestones. The competitive landscape includes other developers of aldose reductase inhibitors and rare-disease therapies, alongside larger pharmaceutical companies with more extensive product pipelines.

TL;DR

Cycle Group Holdings submitted a tender offer on December 11, 2025, proposing $0.088 per APLT share plus a contingent value right of up to $0.40. Shares were priced at $0.14 on December 12, 2025, down 35.45%. Key pipeline developments include Phase 3 data for SORD deficiency and Phase 2 readiness for PMM2-CDG. The company's future outlook is contingent upon successful milestone attainment, the completion of the tender offer process, and ongoing clinical developments.